

CSD/BM/SE/2025-2026

May 13, 2025

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on Tuesday, May 13, 2025

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 13, 2025, has *inter-alia* considered and approved the following along with other business matters.

1. Approved the Audited Standalone and Consolidated Financial Results

Took on record and approved the attached Audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and financial year ended **March 31, 2025** pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Audit Reports of the Statutory Auditors.

2. Increase in the Authorized Share Capital

Increase in the Authorized Share Capital of the Company from ₹ 30,00,00,000 (Rupees Thirty Crore Only) divided into 30,00,00,000 (Thirty Crore) Equity Shares of ₹ 1/- each to ₹ 50,00,00,000 (Rupees Fifty Crore Only) divided into 50,00,00,000 (Fifty Crore) Equity Shares of ₹ 1/- each and consequential alteration in Clause V of the Memorandum of Association of the Company, subject to the approval of shareholders of the Company.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure A**.

3. The issue of warrants convertible into equity shares of the Company on preferential basis to Promoter Group entity and to certain Non-Promoter Persons/ Entities

Issuance of up to **6,40,02,999** (Six Crore Forty Lakhs Two Thousand Nine Hundred Ninety-Nine) fully Convertible Equity Warrants on Preferential Basis to the Promoter group entity of the Company and to certain non-promoter persons/ entities at a price of ₹ 134/- per warrant aggregating up to ₹ **857,64,01,866/-** (Rupees Eight Hundred Fifty Seven Crores Sixty Four Lakhs One Thousand Eight Hundred Sixty Six only), as mentioned in **Annexure B** (the "Proposed Allottees") in accordance with the provisions of the Companies Act, 2013, Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable statutory provisions and subject to the approval of shareholders in the Extra-Ordinary General Meeting of the Company;

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure B**.

4. Re-appointment of Whole-time Director

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors at its meeting held today i.e. May 13, 2025 has, based on the recommendations of Nomination and Remuneration Committee and Audit Committee in the respective meetings held on 13th May 2025, considered and approved the re-appointment of Smt. Sudharani Jasti (DIN: 00277998) as Whole-time Director of the Company for a further period of five (5) years commencing from November 01, 2025 and subject to the approval of the shareholders of the Company.

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure C**.

5. Extra-Ordinary General Meeting (EGM)

The convening the Extra-Ordinary General Meeting of the Company to be held on **Thursday, 05th June, 2025** seeking the approval of the Shareholders of the Company for the issuance of fully convertible warrants on preferential basis.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

6. Approved the amendment to “Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information and Policy on Determination of Legitimate Purpose” in pursuance to the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The updated “Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information and Policy on Determination of Legitimate Purpose” is uploaded on our company’s website at <https://www.suven.com/policiesdocuments.aspx>.

7. Appointment of Secretarial Auditors

Appointment of M/s. DVM & Associates LLP, Company Secretaries in Practice, (ICSI Firm Registration Number: L2017KR002100) as Secretarial Auditors of the Company, for a term of five consecutive years, commencing i.e. from FY 2025-26 to FY 2029-30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting;

Disclosure in respect of appointment of Secretarial Auditors as per the SEBI Circular, is enclosed herewith as ‘**Annexure D**’

8. Annual General Meeting (AGM)

The Board also approved Notice convening the 36th Annual General Meeting of the Company will be held on Friday, the August 22, 2025 through VC/OAVM in compliance with Ministry of Corporate Affairs General Circular No.09/2024 dated September 19, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133, dated October 3, 2024 issued by Securities and Exchange Board of India ("SEBI Circular").

Further, we are enclosing herewith the following documents:

- a) Audited Standalone and Consolidated Financial Results for the quarter and for the financial year ended 31st March, 2025
- b) Auditor’s Reports of the Statutory Auditors on the Financial Results and
- c) Declaration in respect of Audit Reports with unmodified opinion
- d) Press Release

Update on patents during this period can be viewed at: <https://www.suven.com/Patentupdates.aspx>

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

We request you to take these documents on your records. The Board Meeting commenced at 11:00 A.M. and concluded at 12:15 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Annexure A
Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No	Particulars	Details
1)	Amendments to Memorandum of Association of listed entity, in brief	<p>Pursuant to the proposed increase in the authorized share capital of the company, subject to the approval of the Shareholders of the company, it is proposed to substitute the existing Clause V of the Memorandum of Association with the following new Clause V</p> <p><i>“V. The Authorized Share Capital of the Company is ₹ 50,00,00,000 (Rupees Fifty Crores only) divided into 50,00,00,000 (Fifty Crores) Equity Shares of ₹ 1/- (Rupee One only) each.”</i></p>
2)	Amendments to articles of association of listed entity, in brief	Not applicable

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Annexure B
Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. no.	particulars	details																																													
a)	type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Convertible Warrants																																													
b)	type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.);	Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations and other applicable law.																																													
c)	total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Up to 6,40,02,999 Convertible Warrants of face value of ₹ 1/- each at an issue price of ₹ 134/- per warrant, for an aggregate consideration of up to ₹ 857,64,01,866/- to Promoter Group entity and to certain non-promoter persons/ entities.																																													
d)	in case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):																																														
	i. number of investors;	23																																													
	ii. names of the investors; post allotment of securities - outcome of the subscription, issue price/ allotted price (in case of convertibles),	<table> <tr> <th></th><th>Particulars</th><th>No. of Convertible Warrants to be allotted</th></tr> <tr> <td></td><td>Promoter Group entity</td><td></td></tr> <tr> <td>1.</td><td>Jasti Property and Equity Holdings Private Limited (<i>In its capacity as sole trustee of Jasti Family Trust</i>)</td><td>3,17,68,764</td></tr> <tr> <td></td><td>Non-promoter persons/entities</td><td></td></tr> <tr> <td>2.</td><td>QUANT MUTUAL FUND</td><td>47,01,490</td></tr> <tr> <td>3.</td><td>TEJAS TRIVEDI</td><td>37,31,343</td></tr> <tr> <td>4.</td><td>ABAKKUS DIVERSIFIED ALPHA FUND</td><td>29,85,000</td></tr> <tr> <td>5.</td><td>3P INDIA EQUITY FUND 1</td><td>33,58,209</td></tr> <tr> <td>6.</td><td>KETAN CHHOTALAL SHETH</td><td>20,00,000</td></tr> <tr> <td>7.</td><td>ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED</td><td>18,65,670</td></tr> <tr> <td>8.</td><td>ARUN NAHAR</td><td>15,00,000</td></tr> <tr> <td>9.</td><td>JAGDISH N MASTER</td><td>15,00,000</td></tr> <tr> <td>10.</td><td>COBRA INDIA (MAURITIUS) LIMITED</td><td>15,00,000</td></tr> <tr> <td>11.</td><td>NILESH KISHORE SHAH</td><td>12,00,000</td></tr> <tr> <td>12.</td><td>NIMESH ARVIND DOSHI</td><td>11,94,100</td></tr> </table>		Particulars	No. of Convertible Warrants to be allotted		Promoter Group entity		1.	Jasti Property and Equity Holdings Private Limited (<i>In its capacity as sole trustee of Jasti Family Trust</i>)	3,17,68,764		Non-promoter persons/entities		2.	QUANT MUTUAL FUND	47,01,490	3.	TEJAS TRIVEDI	37,31,343	4.	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000	5.	3P INDIA EQUITY FUND 1	33,58,209	6.	KETAN CHHOTALAL SHETH	20,00,000	7.	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670	8.	ARUN NAHAR	15,00,000	9.	JAGDISH N MASTER	15,00,000	10.	COBRA INDIA (MAURITIUS) LIMITED	15,00,000	11.	NILESH KISHORE SHAH	12,00,000	12.	NIMESH ARVIND DOSHI	11,94,100
	Particulars	No. of Convertible Warrants to be allotted																																													
	Promoter Group entity																																														
1.	Jasti Property and Equity Holdings Private Limited (<i>In its capacity as sole trustee of Jasti Family Trust</i>)	3,17,68,764																																													
	Non-promoter persons/entities																																														
2.	QUANT MUTUAL FUND	47,01,490																																													
3.	TEJAS TRIVEDI	37,31,343																																													
4.	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000																																													
5.	3P INDIA EQUITY FUND 1	33,58,209																																													
6.	KETAN CHHOTALAL SHETH	20,00,000																																													
7.	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670																																													
8.	ARUN NAHAR	15,00,000																																													
9.	JAGDISH N MASTER	15,00,000																																													
10.	COBRA INDIA (MAURITIUS) LIMITED	15,00,000																																													
11.	NILESH KISHORE SHAH	12,00,000																																													
12.	NIMESH ARVIND DOSHI	11,94,100																																													

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

		13.	ORACULAR ADVISORY PRIVATE LIMITED	11,25,000
		14.	3P INDIA EQUITY FUND 1M	11,19,403
		15.	ATMAN INVESTMENTS PRIVATE LIMITED	10,00,000
		16.	TRISHAKTI POWER HOLDINGS PRIVATE LIMITED	10,00,000
		17.	TIKRI PARTNERS LLP	7,46,260
		18.	CAMPBELL ADVERTISING PRIVATE LIMITED	4,47,760
		19.	NIMISH CHANDULAL SHAH	3,60,000
		20.	SHARAD NANDLAL SHAH	3,00,000
		21.	NEHA IYENGAR	3,00,000
		22.	SHANTIKUMAR GIRDHARLAL SHAH	1,50,000
		23.	CHARU MAHENDRA PARIKH	1,50,000
	iii. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Not applicable		
e)	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable		

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Annexure C
Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No	Particulars	Details
3)	Name of Director	SUDHARANI JASTI
4)	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment as Whole-time Director (Executive) of the Board.
5)	Date of appointment & Term of appointment	May 13, 2025 & 5 (five) years from November 1, 2025.
6)	Brief profile (in case of appointment)	Smt. Sudharani Jasti is a Graduate in Science from Andhra University. Smt. Sudharani Jasti had been on the Board since inception of the Company and successfully managing & overseeing the company's affairs as Whole-time Director providing the right direction and leadership in administration and all governance matters.
7)	Disclosure of relationships between directors (in case of appointment of a director)	Smt. Sudharani Jasti is spouse of Shri Venkateswarlu Jasti. Except this relationship, both the Directors are not related to any other Directors on the Board of the Company.
8)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	We hereby confirm that Smt. Sudharani Jasti is not debarred from holding the office of a Director by virtue of any SEBI Order or any other such authority.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Annexure D

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No	Particulars	Details
1)	Reason for change viz. appointment	Appointment of DVM & Associates LLP, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: L2017KR002100), as Secretarial Auditors of the Company.
2)	Date of appointment & Term of appointment	The Board at its meeting held on May 13, 2025, approved the appointment of M/s. DVM & Associates LLP as Secretarial Auditors of the Company, for a term of five consecutive years i.e. from FY 2025-2026 till FY 2029-2030, subject to approval of the shareholders.
3)	Brief profile (in case of appointment)	<p>DVM & Associates LLP was established in the Year 2017; the firm is ISO 9001:2015 certified firm of Company Secretaries. Firm is registered as a Practicing Company Secretaries firm with The Institute of Company Secretaries of India (ICSI) and has Peer Review Certificate No. 890/2020 issued by the Institute of Company Secretaries of India (ICSI).</p> <p>Their expertise covers Corporate legal compliances, Corporate Governance, Advisory and Consulting.</p>
4)	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Suven Life Sciences Limited


Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com




SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, 6th floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034
STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2025 &
UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025

Rs. In Lakhs						
		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2025	31/12/2024	31/03/2024	31/03/2025	31/03/2024
		Refer note.7	Un-Audited	Refer note.7	Audited	Audited
1	Income					
	Revenue from operations	146.70	160.99	238.52	665.58	1,169.29
	Other Income	119.08	156.93	428.31	1,072.59	2,113.00
	Total income	265.78	317.92	666.83	1,738.17	3,282.29
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	606.61	486.58	346.35	2,082.49	1,653.37
	d) Finance costs	-	0.79	2.99	4.66	15.84
	e) Depreciation and amortisation expense	134.67	153.35	151.04	582.17	650.22
	f) R & D Expenses	848.73	826.49	417.59	3,043.16	2,038.87
	g) Other Expenses	182.78	177.90	161.49	733.67	570.72
	Total expenses	1,772.79	1,645.11	1,079.46	6,446.15	4,929.02
3	Profit before exceptional items & Tax (1-2)	(1,507.01)	(1,327.19)	(412.63)	(4,707.98)	(1,646.73)
4	Exceptional Items	-	-	-	-	745.66
5	Profit before Tax (3-4)	(1,507.01)	(1,327.19)	(412.63)	(4,707.98)	(901.07)
6	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	(100.24)	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,507.01)	(1,327.19)	(312.39)	(4,707.98)	(800.83)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(4.64)	(0.45)	(20.24)	(5.99)	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income / (Loss)	(4.64)	(0.45)	(20.24)	(5.99)	(6.00)
9	Total Comprehensive Income/ (Loss) for the period (7+8)	(1,511.65)	(1,327.64)	(332.63)	(4,713.97)	(806.83)
10	Paid-up equity share capital	2,180.74	2,180.74	2,180.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity		-	-	77,770.36	82,356.88
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic (Based on weighted average no.of shares)	(0.69)	(0.61)	(0.14)	(2.16)	(0.37)
	b) Diluted (Based on weighted average no.of shares)	(0.69)	(0.61)	(0.14)	(2.16)	(0.37)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



Sl. No.	PARTICULARS	CONSOLIDATED				
		For the Quarter Ended			For the year ended	
		31/03/2025	31/12/2024	31/03/2024	31/03/2025	31/03/2024
		Refer note.7	Un-Audited	Refer note.7	Audited	Audited
1	Income					
	Revenue from operations	146.70	160.99	238.52	665.58	1,169.29
	Other Income	122.25	163.05	428.31	1,089.69	2,113.00
	Total income	268.95	324.04	666.83	1,755.27	3,282.29
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	606.61	486.58	346.48	2,082.49	1,898.75
	d) Finance costs	-	0.79	2.99	4.66	15.84
	e) Depreciation and amortisation expense	134.67	153.35	150.84	582.17	650.22
	f) R & D Expenses	3,732.50	3,413.32	2,752.17	14,396.18	11,442.72
	g) Other Expenses	189.66	181.66	168.66	764.27	628.29
	Total expenses	4,663.44	4,235.70	3,421.14	17,829.77	14,635.82
3	Profit before exceptional items, Tax (1-2)	(4,394.49)	(3,911.66)	(2,754.31)	(16,074.50)	(11,353.53)
4	Exceptional Items	-	-	-	-	745.66
5	Profit before Tax (3-4)	(4,394.49)	(3,911.66)	(2,754.31)	(16,074.50)	(10,607.87)
6	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	(100.24)	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(4,394.49)	(3,911.66)	(2,654.07)	(16,074.50)	(10,507.63)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(4.64)	(0.45)	(20.24)	(5.99)	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	(52.34)	-	-	(52.34)	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income / (Loss)	(56.98)	(0.45)	(20.24)	(58.33)	(6.00)
9	Total Comprehensive Income/ (Loss) for the period (7+8)	(4,451.47)	(3,912.11)	(2,674.31)	(16,132.83)	(10,513.63)
10	Paid-up equity share capital Face Value of the Share	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00
11	Other Equity	-	-	-	8,817.94	24,823.32
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic (Based on weighted average no.of shares)	(2.02)	(1.79)	(1.22)	(7.37)	(4.82)
	b) Diluted(Based on weighted average no.of shares)	(2.02)	(1.79)	(1.22)	(7.37)	(4.82)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 13, 2025. The results for the year ended March 31, 2025 has been audited and for the quarter ended March 31, 2025 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc.

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The Company has allotted 7,26,91,239 equity shares amounting to Rs.39,980.18 lakhs through rights issue on November 16, 2022.

Summary of Utilisation of Proceeds of Rights issue

Particulars	Amount Rs.In lakhs
Amount Raised through Rights Issue of Shares	39,980.18
Less: Rights Issue Expenses	(280.00)
Less: Amount Utilised	(39,700.18)
Balance Amount	0.00

6) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024. For the period ended March 31, 2025, the employee benefit expense includes a charge of Rs.127.45 Lakhs in respect of equity-settled share-based payment transactions, in accordance with Ind AS 102 - 'Share-based Payment'.


7) The figures for the current quarter and quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2025 and March 31, 2024, respectively and published year to date figures upto 3rd quarter ended 31st December 2024 and 31st December 2023, respectively, regrouped as necessary.

Place : Hyderabad
Date: May 13, 2025



For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & MD
DIN: 00278028


SUVEN LIFE SCIENCES LTD				
Regd. Off:SDE Serene Chambers,6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034				
Statement of Assets & Liabilities				
Rs.in Lakhs				
Particulars	Standalone as at		Consolidated as at	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
A ASSETS				
1 Non-current assets				
(a) Property,Plant and Equipment	5,947.19	2,749.51	5,947.19	2,749.51
(b) Capital Work-in-Progress	0.97	-	0.97	-
(c) Other Intangible Assets	18.08	19.86	18.08	19.86
(d) Right of use Assets	-	51.46	-	51.46
(e) Financial Assets				
I. Investments	69,147.16	57,711.34	-	-
II.Other financial assets	4.86	1.50	4.86	1.50
(f) Other Non-current Assets	-	0.59	-	0.59
Total Non-Current assets	75,118.26	60,534.26	5,971.10	2,822.92
2 Current assets				
Inventories	23.75	70.85	23.75	70.85
(a) Financial Assets				
I. Investments in mutual funds	2,227.85	7,593.51	2,227.85	7,593.51
II.Trade Receivables	133.64	128.60	133.64	128.60
III.Cash and Cash equivalents	46.35	439.97	1,502.55	1,493.24
IV. Bank balances otherthan (III) above	1,950.00	14,904.71	2,270.08	14,904.71
V. Other financial assets	7.60	220.18	7.60	220.18
(b) Current Tax asset(net)	119.00	179.51	119.00	179.51
(c) Other current assets	1,262.76	1,076.75	1,262.76	1,076.75
Total Current assets	5,770.95	24,614.08	7,547.23	25,667.35
TOTAL - ASSETS	80,889.21	85,148.34	13,518.33	28,490.27
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,180.74	2,180.74	2,180.74	2,180.74
(b) Other Equity	77,770.36	82,356.88	8,817.94	24,823.32
Total Equity	79,951.10	84,537.62	10,998.68	27,004.06
2 LIABILITIES				
Non-current liabilities				
Provision for Employee benefits	171.05	134.60	171.05	134.60
Total non-current liabilities	171.05	134.60	171.05	134.60
Current liabilities				
(a) Financial Liabilities				
I. Lease Liabilities	-	70.97	-	70.97
II. Trade payables				
a) To Micro & Small Enterprises	38.42	17.83	38.42	17.83
b) Other than Micro & Small Enterprises	484.24	188.98	484.24	188.98
III. Other Financial Liabilities	20.07	35.83	1,601.61	909.09
(b) Provision Employee benefits	164.05	111.67	164.05	111.67
(c) Other Current liabilities	60.28	50.84	60.28	53.07
Total - Current liabilities	767.06	476.12	2,348.60	1,351.61
Total Liabilities	938.11	610.72	2,519.65	1,486.21
TOTAL - EQUITY AND LIABILITIES	80,889.21	85,148.34	13,518.33	28,490.27
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> <p>Place : Hyderabad</p> <p>Date : May 13, 2025</p> </div> <div style="text-align: center;">  </div> <div> <p>For SUVEN LIFE SCIENCES LTD</p> <p><i>Venkat Jasti</i></p> <p>VENKAT JASTI</p> <p>Chairman & MD</p> <p>DIN: 00278028</p> </div> </div>				

SUVEN LIFE SCIENCES LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2025

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2025	For the year ended 31st March 2024
A. Cash flow from operating activities		
Profit/(Loss) before tax	(4,707.98)	(901.07)
Adjustments :		
Depreciation and amortisation expense	530.71	581.60
ESOP expenses	127.45	-
Interest Income	(557.32)	(1,642.52)
Finance Cost	4.66	15.84
Insurance Receipt	-	(745.66)
Gain on Unrealised Current Investment	(497.56)	(454.91)
Operating profit before working capital changes	(5,100.04)	(3,146.72)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(5.05)	(47.86)
Inventories	47.10	(70.84)
Other non current assets	52.05	85.77
Other current assets	(186.01)	511.21
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	315.85	40.32
Long term provisions	36.45	(53.64)
Short term provision	46.40	2.92
Other financial liabilities	(15.77)	(0.29)
Other current liabilities	9.44	5.14
Cash generated from operating activities	(4,799.58)	(2,673.99)
Income taxes paid (net of refunds)	(60.51)	(617.69)
Net Cash flows from operating activities	(4,739.07)	(2,056.30)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(3,727.58)	242.12
Other financial assets	209.22	10,256.50
Interest received	557.32	1,642.52
Changes in Investments	(11,435.81)	(9,525.72)
Sale/(purchase) of mutual funds	5,863.22	(2,504.72)
Bank balances not considered as cash and cash equivalents	12,954.71	(178.55)
Net cash flow from /(used in) investing activities	4,421.08	(67.85)
C. Cash flows from financing activities		
Changes In Lease Liability	(70.97)	(89.56)
Finance Cost	(4.66)	(15.84)
Net cash flow from /(used In) financing activities	(75.63)	(105.40)
Net increase/(decrease) in cash and cash equivalents	(393.62)	(2,229.55)
Cash and cash equivalents as at the beginning of the year	439.97	2,669.52
Cash and cash equivalents at the end of the year	46.35	439.97
Cash and cash equivalents	46.35	439.97
Balances per statement of cash flows	46.35	439.97



Place : Hyderabad
Date : May 13, 2025


For SUVEN LIFE SCIENCES LTD

Venkata Jasti

VENKAT JASTI
Chairman & MD
DIN: 00278028

SUVEN LIFE SCIENCES LIMITED
Consolidated Statement of Cash flows for the year ended 31st March, 2025
(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2025	For the year ended 31st March 2024
A. Cash flow from operating activities		
Profit/(Loss) before tax	(16,074.50)	(10,607.87)
Adjustments :		
Depreciation and amortisation expense	530.71	581.60
ESOP expenses	127.45	-
Interest Income	(568.25)	(1,642.52)
Finance Cost	4.66	15.84
Insurance Receipt	-	(745.65)
Gain on Unrealised Current Investment	(497.56)	(454.91)
Operating profit before working capital changes	(16,477.49)	(12,853.51)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(5.05)	(47.86)
Inventories	47.10	(70.84)
Other non current assets	52.05	85.77
Other current assets	(186.01)	511.21
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	315.85	40.32
Long term provisions	36.45	(53.64)
Short term provision	46.40	2.92
Other financial liabilities	690.29	222.49
Other current liabilities	9.44	(1.45)
Cash generated from operating activities	(15,470.97)	(12,164.59)
Income taxes paid (net of refunds)	(60.51)	(617.69)
Net Cash flows from operating activities	(15,410.46)	(11,546.90)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(3,727.58)	242.12
Other financial assets	209.22	10,256.50
Interest received	568.25	1,642.52
Sale/(purchase) of mutual funds	5,863.22	(2,504.72)
Foreign currency translation reserve	(52.34)	(14.24)
Bank balances not considered as cash and cash equivalents	12,634.63	(178.55)
Net cash flow from /(used in) investing activities	15,495.40	9,443.63
C. Cash flows from financing activities		
Changes In Lease Liability	(70.97)	(89.56)
Finance Cost	(4.66)	(15.84)
Net cash flow from /(used In) financing activities	(75.63)	(105.40)
Net increase/(decrease) in cash and cash equivalents	9.31	(2,208.67)
Cash and cash equivalents as at the beginning of the year	1,493.24	3,701.91
Cash and cash equivalents at the end of the year	1,502.55	1,493.24
Cash and cash equivalents	1,502.55	1,493.24
Balances per statement of cash flows	1,502.55	1,493.24



Place : Hyderabad
Date : May 13, 2025

For SUVEN LIFE SCIENCES LTD

Venkat Jasti

VENKAT JASTI
Chairman & MD
DIN: 00278028

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

To
The Board of Directors of
Suven Life Sciences limited

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2025 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Year Ended March 31, 2025 and unaudited Standalone Financial Results for the Quarter Ended March 31, 2025 ("the Statement") of **Suven Life Sciences Limited** ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2025:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and Fairview in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and total comprehensive loss and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2025

With respect to the Standalone Financial Results for the quarter ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2025



13/05/2025

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2025 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the net loss and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company. Auditor's Responsibilities

Auditors Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2025 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.



13/05/2025

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.



13/05/2025

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2025

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- Attention is drawn to Note 7 to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- Attention is drawn to Note 7 to the Statement, the figures for the corresponding quarter ended March 31, 2024 are the balancing figures between the annual audited figures for the full financial year then ended and the year-to-date figures for the 9 months period ended December 31, 2023. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2024. Our report is not modified in respect of this matter.

For M/s.KARVY & CO

Chartered Accountants

(Firm Registration No.001757S)



AJAYKUMAR KOSARAJU

Partner

M.No. 021989

UDIN:

25021989BMITART1688

Place: Hyderabad

Date : 13/05/2025



13/05/2025

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

To
The Board of Directors of
Suven Life Sciences Limited

Opinion and Conclusion

We have(a) audited the Consolidated Financial Results for the year ended March 31,2025 and (b)reviewed the Consolidated Financial Results for the quarter ended March 31,2025 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Statement of Audited Consolidated Financial Results for the Year Ended March 31, 2025 and Unaudited Consolidated Financial Results for the Quarter Ended March 31, 2025" of **Suven Life Sciences Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") for the quarter and year ended March 31, 2025, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

1) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2025:


a) includes the results of the following entities:

Name of the Company	Country	Relationship
SUVEN NUEROSCIENCES INC	USA	Wholly Owned Subsidiary

- b) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- c) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net loss and consolidated total comprehensive loss and other financial information of the Group for the year ended March 31,2025.

2) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2025 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the



13/05/2025

recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph(a) of Auditor's Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net loss and consolidated other comprehensive loss and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.



13/05/2025

Auditor's Responsibilities for

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities

13/05/2025



included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- Attention is drawn to Note 7 to the Statement which states that the Consolidated Financial Results includes the results for the Quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year of the financial results which were subject to limited review by us. Our report is not modified in respect of this matter.
- Attention is drawn to Note 7 to the Statement, the figures for the corresponding quarter ended March 31, 2024 are the balancing figures between the annual audited figures for the year then ended and the year-to-date figures for the 9 months period ended December 31, 2023. We have not issued separate limited review report on the results

13/05/2025



and figures for the quarter ended March 31, 2024. Our report is not modified in respect of this matter.

- We did not audit financial information of subsidiary included in the consolidated financial results, whose financial information reflect total assets of Rs.1,776.28 lakhs as at March 31, 2025 and total revenues of Rs. 17.10 lakhs and Rs.3.17 lakhs for the quarter and year ended March 31, 2025 respectively, total net loss after tax of Rs.(2,887.47) lakhs and Rs.(11,366.52) lakhs for the quarter and year ended March 31, 2025 respectively and total comprehensive Loss of Rs.(2,939.81) lakhs and Rs.(11,418.86) Lakhs for the quarter and year ended March 31, 2025 respectively and net cash inflows of Rs.402.93 lakhs for the year ended March 31, 2025, as considered in the Statement. This financial information has been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For KARVY & CO

Chartered Accountants

(Firm Registration No .001757S)



AJAYKUMAR KOSARAJU

Partner

M.No. 021989

UDIN:

25021989BM1ARJ3564

Place: Hyderabad

Date : 13/05/2025



13/05/2025

SUVEN/NSE&BSE/AFR/2025-26

May 13, 2025

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Declaration in respect of Audit Reports with unmodified opinion for the financial year ended 31st March 2025

.....

We hereby declare that the Statutory Auditors of the Company, M/s. KARVY & Co., Chartered Accountants have issued an Audit Reports with unmodified opinion on Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2025.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

Venkateswarlu Jasti
Chairman & MD

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

News Release

HYDERABAD, INDIA (13 May 2025) - Suven Life Sciences Limited ("Suven") today announced audited financial results for the quarter and year ended 31 March 2025. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13 May 2025 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
Revenue	26.90	32.40	66.68	175.53	328.23
R&D and Operational expenses	452.88	408.16	326.73	1,724.29	1,396.98
Depreciation and Amortisation	13.47	15.34	15.08	58.22	65.02
Finance cost	-	0.08	0.30	0.47	1.58
Total expenses	466.34	423.57	342.11	1,782.98	1,463.58
Exceptional items (insurance claim received)	-	-	-	-	74.57
Tax	-	-	(10.02)	-	(10.02)
Profit/(Loss) After Tax for the period/year	(439.45)	(391.17)	(265.41)	(1,607.45)	(1,050.76)
Other comprehensive income	(5.70)	(0.05)	(2.02)	(5.83)	(0.60)
Total comprehensive income	(445.15)	(391.21)	(267.43)	(1,613.28)	(1,051.36)
Paid up equity capital	218.07	218.07	218.07	218.07	218.07
Earnings per share of Rs.1 each (EPS)	(2.02)	(1.79)	(1.22)	(7.37)	(4.82)

- (a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
- (b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
- (c) Clinical development pipeline:
- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26.
 - SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q2-FY26.
 - SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in USA successfully completed. Initiated Phase 2B clinical study in Q1-FY26.
 - SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during FY26.
 - SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule.
- (d) Board of Directors of Suven approved fund raising of INR 8,576.40 million through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programs and general corporate purposes and CAPEX for creating new R&D facility. More information will be provided in the notice to the EGM proposed.
- (e) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and USA.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com